What changed leads this NU573 follow-up: a composite supervisor with gout has had one flare and a urate still above six, justifying a bracketed dose increase and continued prophylaxis. Searches like "nu 573 unit 6 assignment example", "nu573 unit 6 sample" and "nu573 unit 6 example" land here.
Chronic Disease Follow-Up Note: Gout Three Months Into Urate-Lowering Therapy, Improving but Not at Target
[Student Name]
Purdue University Global
NU573: AGNP I Clinical - Adolescent and Adult Focus
Unit 6 Chronic Disease Follow-Up Note
[Instructor Name]
[Date]
The patient is a composite; values, doses and dates are bracketed.
Interval Change
One flare in the left great toe [three] weeks ago, lasting four days, treated with his rescue [colchicine] supply. Serum urate [6.8] mg/dL today, down from [8.9] at baseline three months ago.
Background
Gout with [three] flares in the year before therapy; see problem list. Also hypertension on [hydrochlorothiazide].
Interval History
Taking [allopurinol] [200 mg] daily and [colchicine] [0.6 mg] daily for prophylaxis, missing about one dose a week. Beer cut from nightly to weekends, about [six] a week. No change in diet beyond less beer. No rash, no mouth sores, no muscle weakness.
Examination
Blood pressure [134/84]. No tophi on the ears, elbows, hands or feet. Left first metatarsophalangeal joint quiet: no warmth, swelling or tenderness. No other joints involved.
Data
Urate [6.8] mg/dL. eGFR [78]. ALT and AST normal. Complete blood count normal.
Assessment
Gout, improving, not at target. The urate has fallen by 2.1 mg/dL but is still above 6, so the dose is not yet enough, and a flare in the early months of therapy is expected rather than a sign of failure. Flares often increase when urate-lowering therapy begins, as urate crystals are mobilized, which is why prophylaxis continues. No tophi, so the target remains below 6 mg/dL, not below 5.
Plan
1. Urate-lowering therapy: increase [allopurinol] from [200 mg] to [300 mg] daily. The ACR guideline recommends a treat-to-target strategy with a serum urate goal below 6 mg/dL, titrating the dose every few weeks until the target is reached (FitzGerald et al., 2020). His kidney function allows the increase.
2. Prophylaxis: continue [colchicine] [0.6 mg] daily for [three to six] months after starting therapy, and longer if flares continue, as the guideline recommends (FitzGerald et al., 2020).
3. Adherence: a weekly pill organizer; he agreed to take both at breakfast.
4. Medication review: [hydrochlorothiazide] raises serum urate by reducing its excretion. In a population study of people with hypertension, diuretics were associated with a higher risk of incident gout, while losartan and calcium channel blockers were associated with a lower risk (Choi et al., 2012). Option to switch to [losartan] or [amlodipine] discussed; [he chose to switch to losartan, with a potassium and creatinine check in two weeks].
5. Lifestyle: continue cutting back on beer, which raises urate and triggers flares; limit sugary drinks. Diet alone will not reach target but helps (Dalbeth et al., 2021).
6. Flare plan: rescue [colchicine] as before; call if a flare lasts more than [three] days.
Why the Dose Rises in Steps
The allopurinol dose is raised gradually rather than set at the full expected dose from the start. Starting low and titrating reduces early flares and, in the guideline's reasoning, the risk of allopurinol hypersensitivity, a rare but severe reaction (FitzGerald et al., 2020). The trade-off is time: reaching target can take several months of adjustments, and each step needs a urate check. He was told this plainly, so that a second visit without reaching target would not feel like failure. Most people reach a urate below 6 mg/dL on 300 mg or more, and the dose can go higher with normal kidney function if needed.
What He Was Told
Gout is caused by urate crystals, and the goal is to dissolve them by keeping urate low for good. A flare in the first months is common and does not mean the medicine is failing. Taking the tablets every day matters more than any food rule. And the medicine is usually lifelong.
Follow-Up
Urate in [four to five] weeks after the dose increase, with a visit on [date]. Call sooner for a rash, which could signal a hypersensitivity reaction to allopurinol, or for a flare not settling in three days.
References
Choi, H. K., Soriano, L. C., Zhang, Y., & RodrÃguez, L. A. G. (2012). Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ, 344, d8190. https://doi.org/10.1136/bmj.d8190
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021). Gout. The Lancet, 397(10287), 1843-1855. https://doi.org/10.1016/S0140-6736(21)00569-9
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., ... Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
How this NU573 Unit 6 example is structured
Built so a colleague could stop after the first three lines and still know what happened, the note puts interval change first and shrinks background to one sentence referring to the problem list. Each later section answers the question the interval raised. The exam looks for tophi and active synovitis because those alter the target; the labs check kidney function because it governs dosing. The assessment carries a status word, improving, and the reason for it. The plan applies the treat-to-target approach of the 2020 ACR gout guideline: urate below 6 mg/dL, dose titration at intervals, and prophylaxis for three to six months after therapy begins. A medication review notes that his thiazide raises urate and records the option of switching, in brackets. The follow-up line names a date and a threshold for earlier contact.
Get an NU573 Unit 6 example written to your instructions
Send the prior visit summary when the case includes one, since a follow-up note has to build on it, along with the condition being followed and the interval your case describes. SOAP and problem-oriented formats both work. The first sample is free and arrives in 24-48h, laid out to match your rubric. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU573 Unit 6 questions, answered
How much history belongs in a chronic follow-up note?
Very little beyond what changed. A single line referring to the diagnosis and baseline is usually enough, with the problem list carrying the rest. The note's job is to record what happened in the interval and what was decided because of it, and graders often penalize retold history that buries the interval.
What is treat-to-target in gout?
It means adjusting urate-lowering therapy until the serum urate falls below a set level, usually six milligrams per deciliter, rather than treating only when symptoms appear. The 2020 ACR guideline recommends this approach along with flare prophylaxis when therapy starts. A follow-up note shows it by reporting the level and acting on it.
Can the note use a status word like stable?
Yes, with a reason. Stable, improving or worsening followed by the finding that supports it gives the next clinician a quick picture. The word alone tells a reader little, and many rubrics mark down status labels that do not point to data from the visit itself.